Rapid evolution in hematology and medical oncology (Hem/Onc) remains a constant challenge. Site of care shifts, continued reimbursement reductions, payer challenges, the exploding diagnostic/reference lab testing market, and many other factors have led Hem/Onc practices to become the most restrictive specialty as it relates to Access for pharmaceutical manufacturers. Adapting to market changes will be critical to the success of Hem/Onc brands.
intelliPoint market research panels consist of physician, practice administrator and payer panels carefully selected for their Influence, Innovation and Expertise. intelliPoint incorporates onPoint’s proprietary access and reimbursement data base and analytics tool to inform questions and market research findings.
- Physician and practice administrator participants represent large community Hem/Onc practices
- Payer participants hail from leading plans active in oncology management
Joint Panel of Practice and Payers:
- Combined working group approach
- Provider/Payer collaborative solutions and testing opportunities
intelliPoint taps into the critical core of practice and payer stakeholders providing solutions, best practices and concept testing for all phases of a Hem/Onc brands life cycle.
focalPoint™ changes the way Biotech/Pharmaceutical manufacturers approach access and reimbursement by identifying opportunities and challenges with real-time data from a unique and differentiable data source.